Search Results  for '4174.TWO'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

OBI Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

21 Jan 2016 GlobalData 38 $300.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical company. The...

11 Dec 2015 GlobalData 40 $300.00

Biotech Sector: 2016 Will be the Year of Triumph

We reiterate our BUY rating on OBI Pharma (4174 TT).

03 Sep 2015 MasterLink Securities Corporation 4 $35.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical compan...

21 Aug 2015 GlobalData 27 $125.00

OBI Pharma (4174 TT); OBI’s New Drug will Bear Fruits despite Confusion in the Market

We reiterate our BUY rating on OBI Pharma (4174 TT).

10 Jun 2015 MasterLink Securities Corporation 5 $46.00

浩鼎(4174): 市場過度解讀,浩鼎新藥終將豐收

重申浩鼎OBI-822為癌症主動免疫療法新藥,潛在價值不可忽視:目前在評價上,在條件不足下雖難以推測PFS中位數,然元富認為,浩鼎OBI-822解盲是應在統計上具有顯著療效,可正面期待,且浩鼎OBI-822並非僅為乳癌藥物,其主動免疫療法以及醣分子機...

05 Jun 2015 MasterLink Securities Corporation 4 $23.00

OBI Pharma, Inc. (4174) - Financial Analysis Review

OBI Pharma, Inc. (4174) - Financial Analysis Review Summary OBI Pharma, Inc. (OBI Pharma) is a biopharmaceutical compan...

07 Apr 2015 GlobalData 25 $125.00

OBI Pharma (4174 TT, IPO NT$310.0, NR): Commercial success hinges on global phase III study

Event OBI Pharma will be listed on Taipei Exchange on 23 March, with an IPO price of NT$310. It is the largest ever biotech I...

19 Mar 2015 KGI Greater China 8 $81.00

浩鼎 (4174 TT, 承銷價NT$310.0, 未評等): 新穎技術,成功商品化尚待全球臨床三期驗證

重要訊息 浩鼎於3/23上櫃交易,以掛牌價310計算,上櫃後市值約624億台幣,為台灣近年來規模最大的生技股承銷案,籌資超過新台幣62億元,因應持續臨床研究發展所需。 評論及分析 OBI-822/821早期研發史。OBI-822為試驗性抗癌...

19 Mar 2015 KGI Greater China 8 $69.00